Lexeo Therapeutics, Inc. Passive Investment Disclosure (>5%)
The Vanguard Group reported beneficial ownership of Lexeo Therapeutics Inc common stock on a passive basis.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
The Vanguard Group reported beneficial ownership of Lexeo Therapeutics Inc common stock on a passive basis. As of the reported event date of 12/31/2025, Vanguard beneficially owned 3,894,310 shares, representing 5.33% of the company’s common stock.
Vanguard reported no sole voting or dispositive power, with shared voting power over 421,792 shares and shared dispositive power over 3,894,310 shares. The filing states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Lexeo.
AI-generated analysis. How Rhea-AI works. Not financial advice.